FRX Forest Road Acquisition Corp

Forest Laboratories, Inc. Announces New Share Repurchase Program NEW YORK, May 10 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) announced today that its Board of Directors has approved a new share repurchase program for up to an additional 25 million shares of its common stock. The authorization will become effective immediately and has no set expiration date. The Company expects to make the repurchases from time to time in the open market depending on market conditions. (Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) The new program is in addition to a 20 million share repurchase program announced on July 20, 2004 and expanded to 30 million shares on December 14, 2004. Under the 30 million share program the Company has repurchased 29,813,500 shares as of May 10, 2005. About Forest Laboratories, Inc. and Its Products Forest Laboratories' growing line of products includes: Lexapro(R) (escitalopram oxalate), an SSRI antidepressant indicated for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda(R) (memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker indicated for the treatment of hypertension; Benicar* HCT(R) (olmesartan medoxomil hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral(R) * (acamprosate calcium), a glutamate receptor modulator, indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation in combination with psychosocial support; and Combunox(TM) (Oxycodone HCl and Ibuprofen), an opioid and NSAID combination indicated for the short-term management of acute, moderate to severe pain. Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements are subject to risks and uncertainties that affect our business, including risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2004, and on form 10-Q for the periods ending June 30,2004, September 30, 200 and December 31, 2004. Actual results may differ materially from those projected. * Benicar is a registered trademark of Sankyo Pharma, Inc., and Campral is a registered trademark under license from Merck Sant� s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany. http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGODATASOURCE: Forest Laboratories, Inc. CONTACT: Charles E. Triano, Vice President - Investor Relations, Forest Laboratories, Inc., +1-212-224-6714, Web site: http://www.frx.com/

Copyright